2016-06-28 | Reiterated Rating | FBR & Co. | Market Perform | $2.00 |
2016-06-28 | Reiterated Rating | Wedbush | Neutral | $1.25 |
2016-06-28 | Reiterated Rating | FBR & Co | Market Perform | $2.00 |
2016-06-15 | Downgrade | Jefferies Group | Buy to Hold | |
2016-06-15 | Downgrade | William Blair | Outperform to Market Perform | $20.00 to $2.00 |
2016-06-15 | Downgrade | Wells Fargo | Outperform to Market Perform | |
2016-06-15 | Downgrade | Morgan Stanley | Overweight to Equal Weight | |
2016-06-15 | Downgrade | Wells Fargo & Co. | Outperform to Market Perform | |
2016-06-14 | Downgrade | FBR & Co. | Outperform to Market Perform | $15.00 to $2.00 |
2016-06-14 | Downgrade | RBC Capital | Outperform to Sector Perform | $12.00 to $2.00 |
2016-06-14 | Downgrade | JMP Securities | Outperform to Market Perform | |
2016-06-14 | Upgrade | Wedbush | Underperform to Neutral | $3.00 to $1.25 |
2016-06-14 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | |
2016-06-14 | Downgrade | Royal Bank Of Canada | Outperform to Sector Perform | $12.00 to $2.00 |
2016-06-13 | Reiterated Rating | FBR & Co. | Buy | |
2016-05-10 | Reiterated Rating | FBR & Co. | Buy | |
2016-05-05 | Reiterated Rating | Wedbush | Underperform | $3.00 |
2016-04-28 | Reiterated Rating | FBR & Co. | Buy | |
2016-04-06 | Reiterated Rating | RBC Capital | Buy | |
2016-03-31 | Reiterated Rating | JPMorgan Chase & Co. | Buy | $10.00 |
2016-03-22 | Downgrade | Wedbush | Neutral to Underperform | $8.00 to $3.00 |
2016-03-09 | Lower Price Target | JMP Securities | Market Outperform | $24.00 to $17.00 |
2016-03-02 | Initiated Coverage | FBR & Co. | Outperform | $15.00 |
2016-02-25 | Lower Price Target | Wedbush | Neutral | $9.00 to $8.00 |
2016-02-24 | Lower Price Target | JPMorgan Chase & Co. | Overweight | $15.00 to $13.00 |
2015-10-11 | Reiterated Rating | William Blair | Outperform | $21.00 |
2015-09-21 | Upgrade | Morgan Stanley | Equal Weight to Overweight | $15.00 to $13.00 |
2015-08-07 | Reiterated Rating | RBC Capital | Outperform | $18.00 to $15.00 |
2015-06-02 | Set Price Target | Jefferies Group | Buy | $18.00 |
2015-05-16 | Reiterated Rating | Stifel Nicolaus | Hold | |
2015-05-10 | Reiterated Rating | Nomura | Neutral to Buy | $17.00 to $13.00 |
2015-05-10 | Reiterated Rating | RBC Capital | Outperform | $20.00 to $18.00 |
2015-05-10 | Reiterated Rating | Nomura Holdings Inc. | Neutral to Buy | $17.00 to $13.00 |
2015-05-06 | Initiated Coverage | Deutsche Bank | Buy | $20.00 |
2015-05-06 | Initiated Coverage | Deutsche Bank AG | Buy | $20.00 |
2015-01-05 | Downgrade | Morgan Stanley | Overweight to Equal Weight | $19.00 to $18.00 |
2014-12-04 | Upgrade | Credit Suisse | Neutral to Outperform | $20.00 to $22.00 |
2014-12-04 | Upgrade | Credit Suisse Group AG | Neutral to Outperform | $20.00 to $22.00 |
2014-10-20 | Resumed | Stifel | Hold | |
2014-10-20 | Initiated Coverage | Stifel Nicolaus | Hold | |
2014-09-05 | Boost Price Target | Nomura | $12.00 to $19.00 | |
2014-09-04 | Boost Price Target | Jefferies Group | Buy | $13.00 to $18.00 |
2014-09-04 | Upgrade | JMP Securities | Market Perform to Outperform | $24.00 |
2014-09-03 | Reiterated Rating | Roth Capital | Positive | |
2014-09-03 | Upgrade | Wedbush | Underperform to Neutral | $9.00 to $15.00 |
2014-08-06 | Upgrade | William Blair | Outperform | |
2014-06-25 | Initiated Coverage | Morgan Stanley | Overweight | $17.00 |
2014-05-09 | Lower Price Target | Wedbush | $10.00 to $9.00 | |
2014-05-07 | Reiterated Rating | Stifel Nicolaus | Buy | $25.00 to $20.00 |
2014-05-07 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $24.00 to $20.00 |
2014-05-07 | Upgrade | Jefferies Group | Hold to Buy | $15.00 to $13.00 |
2014-05-07 | Lower Price Target | Nomura | $17.00 to $12.00 | |
2014-03-03 | Initiated Coverage | Wedbush | Underperform | $10.00 |
2014-02-26 | Boost Price Target | Nomura | $14.00 to $17.00 | |
2014-02-26 | Boost Price Target | Jefferies Group | $13.00 to $15.00 | |
2014-01-08 | Initiated Coverage | Nomura | Neutral | |
2013-12-12 | Downgrade | Credit Suisse | Outperform to Neutral | $20.00 |
2013-09-23 | Initiated Coverage | William Blair | Market Perform | $21.00 |
2013-09-18 | Boost Price Target | Goldman Sachs | $20.00 to $22.00 | |
2009-04-15 | Downgrade | Rodman & Renshaw | Mkt Outperform to Mkt Perform | |
2008-12-11 | Downgrade | Roth Capital | Neutral to Hold | |
2008-10-31 | Upgrade | Susquehanna Financial | Neutral to Positive | |
2008-10-31 | Upgrade | Roth Capital | Hold to Buy | $8 to $6 |
2008-06-06 | Upgrade | Rodman & Renshaw | Mkt Perform to Mkt Outperform | $13 |
2008-01-15 | Initiated | Roth Capital | Buy | $11 |
2007-12-07 | Initiated | Susquehanna Financial | Neutral | |
2007-07-12 | Initiated | Jefferies & Co | Buy | $15 |
2007-01-30 | Initiated | Robert W. Baird | Neutral | $15 |
2016-06-28 | Reiterated Rating | FBR & Co. | Market Perform | $2.00 |
2016-06-28 | Reiterated Rating | Wedbush | Neutral | $1.25 |
2016-06-28 | Reiterated Rating | FBR & Co | Market Perform | $2.00 |
2016-06-15 | Downgrade | Jefferies Group | Buy to Hold | |
2016-06-15 | Downgrade | William Blair | Outperform to Market Perform | $20.00 to $2.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In INFI 0 funds of 2213 total. Show all
Fund name | Ticker shares |
---|
Name Relationship | Total Shares | Holding stocks |
---|---|---|
BVF PARTNERS L P/IL | 1.96% (950473) | ARQL / ARRY / CAPS / CCXI / CNCE / CTIC / INFI / LGND / NBIX / ONTY / PTN / RGDO / RGEN / RIGL / TRGT / XENE / |
BLOCH LAWRENCE E EVP, CFO & CBO | 1.29% (626133) | INFI / |
Perkins Adelene Q Pres & Chief Executive Officer | 1.25% (607252) | BRKR / INFI / |
EVNIN ANTHONY B | 0.24% (118585) | AVEO / CMN / INFI / XLRN / |
LANDER ERIC S | 0.17% (80319) | INFI / |
VENUTI MICHAEL C | 0.10% (50000) | INFI / |
Tasker Seth A General Counsel | 0.08% (41284) | INFI / |
Berkowitz Jeffrey | 0.07% (36131) | ESPR / INFI / WAG / |
Kutok Jeffery Chief Scientific Officer | 0.06% (28626) | INFI / |
SMITH IAN F | 0.05% (22988) | ACOR / INFI / OPHT / VRTX / |
SELBY NORMAN C | 0.02% (10000) | INFI / |
Santabarbara Pedro Chief Medical Officer | 0.02% (9200) | INFI / |